197 related articles for article (PubMed ID: 30659410)
1. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Minisola S; Marin F; Kendler DL; Geusens P; Zerbini CAF; Russo LA; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Moericke R; Bagur A; Lakatos P; López-Romero P; Body JJ
Arch Osteoporos; 2019 Jan; 14(1):10. PubMed ID: 30659410
[TBL] [Abstract][Full Text] [Related]
2. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL; Marin F; Zerbini CAF; Russo LA; Greenspan SL; Zikan V; Bagur A; Malouf-Sierra J; Lakatos P; Fahrleitner-Pammer A; Lespessailles E; Minisola S; Body JJ; Geusens P; Möricke R; López-Romero P
Lancet; 2018 Jan; 391(10117):230-240. PubMed ID: 29129436
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of teriparatide compared with risedronate on FRAX
Body JJ; Marin F; Kendler DL; Zerbini CAF; López-Romero P; Möricke R; Casado E; Fahrleitner-Pammer A; Stepan JJ; Lespessailles E; Minisola S; Geusens P
Osteoporos Int; 2020 Oct; 31(10):1935-1942. PubMed ID: 32474650
[TBL] [Abstract][Full Text] [Related]
4. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial.
Geusens P; Marin F; Kendler DL; Russo LA; Zerbini CA; Minisola S; Body JJ; Lespessailles E; Greenspan SL; Bagur A; Stepan JJ; Lakatos P; Casado E; Moericke R; López-Romero P; Fahrleitner-Pammer A
J Bone Miner Res; 2018 May; 33(5):783-794. PubMed ID: 29329484
[TBL] [Abstract][Full Text] [Related]
5. Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial.
Kendler DL; Marin F; Geusens P; López-Romero P; Lespessailles E; Body JJ; Minisola S
Bone; 2020 Jan; 130():115113. PubMed ID: 31654779
[TBL] [Abstract][Full Text] [Related]
6. Changes in vitamin D metabolites during teriparatide treatment.
Cosman F; Dawson-Hughes B; Wan X; Krege JH
Bone; 2012 Jun; 50(6):1368-71. PubMed ID: 22426307
[TBL] [Abstract][Full Text] [Related]
7. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial.
Geusens P; Kendler DL; Fahrleitner-Pammer A; López-Romero P; Marin F
Calcif Tissue Int; 2020 Jun; 106(6):646-654. PubMed ID: 32157334
[TBL] [Abstract][Full Text] [Related]
9. Effects of Teriparatide Compared with Risedronate on Recovery After Pertrochanteric Hip Fracture: Results of a Randomized, Active-Controlled, Double-Blind Clinical Trial at 26 Weeks.
Aspenberg P; Malouf J; Tarantino U; García-Hernández PA; Corradini C; Overgaard S; Stepan JJ; Borris L; Lespessailles E; Frihagen F; Papavasiliou K; Petto H; Caeiro JR; Marin F
J Bone Joint Surg Am; 2016 Nov; 98(22):1868-1878. PubMed ID: 27852903
[TBL] [Abstract][Full Text] [Related]
10. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
11. Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Chung HY; Koo J; Kwon SK; Kang MI; Moon SH; Park JY; Shin CS; Yoon BK; Yoon HK; Chang JS; Chung YS; Park HM
Clin Interv Aging; 2013; 8():597-603. PubMed ID: 23761968
[TBL] [Abstract][Full Text] [Related]
12. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
14. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
Krege JH; Wan X
Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Chung HY; Chin SO; Kang MI; Koh JM; Moon SH; Yoon BK; Yoon HK; Chung YS; Park HM
Clin Endocrinol (Oxf); 2011 Jun; 74(6):699-704. PubMed ID: 21521310
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of denosumab co-administered with vitamin D and Ca by baseline vitamin D status.
Sugimoto T; Matsumoto T; Hosoi T; Shiraki M; Kobayashi M; Okubo N; Takami H; Nakamura T
J Bone Miner Metab; 2020 Nov; 38(6):848-858. PubMed ID: 32671481
[TBL] [Abstract][Full Text] [Related]
17. Relationship between baseline characteristics and response to risedronate treatment for osteoporosis: data from three Japanese phase III trials.
Mawatari T; Muraoka R; Iwamoto Y
Osteoporos Int; 2017 Apr; 28(4):1279-1286. PubMed ID: 27900428
[TBL] [Abstract][Full Text] [Related]
18. Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.
Dawson-Hughes B; Chen P; Krege JH
J Clin Endocrinol Metab; 2007 Dec; 92(12):4630-6. PubMed ID: 17911178
[TBL] [Abstract][Full Text] [Related]
19. Indirect comparison of teriparatide, denosumab, and oral bisphosphonates for the prevention of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Zhang L; Pang Y; Shi Y; Xu M; Xu X; Zhang J; Ji L; Zhao D
Menopause; 2015 Sep; 22(9):1021-5. PubMed ID: 25944523
[TBL] [Abstract][Full Text] [Related]
20. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
